NEWS

We Work For Health Executive Director Dan Leonard issued the following statement ahead of an anticipated vote “As Congress once again prepares for a long evening of budget reconciliation debates, we urge lawmakers to reject proposals – such as most favored nation (MFN) – that would undermine America’s world leadership in healthcare innovation and industry. MFN and similar government price control mandates would not lower patients’ out-of-pocket expenses, nor would they addres

Illinois is home to a robust biopharmaceutical industry that delivers life-saving cures to patients across the country. In the last 16 months, $2.75 billion in biopharmaceutical investment has flowed into Illinois – fueling continued leadership in research, development, and manufacturing. In Illinois: $575 million investment by AbbVie in North Chicago Over 263k local jobs supported by the industry $101.1 billion in economic output Faster delivery of more innovative cures to

A guest perspective by: Henry Hadad, Senior Vice President, Innovation Law, Bristol Myers Squibb Over the past century, the biopharmaceutical industry has delivered extraordinary advances that have fundamentally transformed human health. Immuno-oncology has extended survival for patients with metastatic melanoma from eight months in the 1990s to six years today. Antiretrovirals allow HIV patients to live normal lives. Antibiotics have slashed mortality from infectious disease

By: Dan Leonard, Executive Director, We Work For Health and Chrissy Buteas, President and Chief Executive Officer, HealthCare Institute of New Jersey Making medicines more affordable is a goal we all share. Patients, employers, innovators, and policymakers recognize that high costs can stand between patients and the care they need. But not every policy that promises lower prices delivers better outcomes. If policymakers were to codify a “most favored nation” (MFN) drug pricin

Anyone who has followed the U.S. biopharmaceutical industry closely since the start of last year is likely aware of the historic investment that companies have made to strengthen the nation's drug innovation infrastructure, including through next-generation manufacturing facilities that can deliver therapies to Americans faster and more safely. We Work For Health has tracked more than $582 billion in announcements since January 2025. While it will take time for the full scope

Intellectual property is the backbone of the biopharma industry’s innovation ecosystem, driving the discovery and development of life‑saving treatments for patients. In recent years, We Work For Health has presented the Healthcare Innovation Leadership Award to policymakers who demonstrate a sustained commitment to protecting the intellectual property framework that fuels medical innovation. The latest honorees are Representatives Brad Knott (R-NC) and Scott Fitzgerald (R

On April 23, We Work For Health hosted a webinar to examine how a Most Favored Nation pricing policy could affect patient access, affordability, and medical innovation, and why the promised savings may not materialize. Drawing on real‑world examples from Europe and other OECD countries, panelists discussed the unintended but very real consequences of implementing and codifying an MFN policy, including reduced access to lifesaving medicines and limited or nonexistent price rel

World Intellectual Property Day is this Sunday, April 26, and it comes at a moment of rapid scientific progress and growing global competition. As innovation accelerates, the systems that support investment, collaboration and long‑term research are under increasing pressure. The decisions made now will shape where breakthroughs are developed and how quickly they reach patients. Ahead of World IP Day, WWFH Executive Director Dan Leonard shares his perspective on why intell